Ai for Business

  Sanofi has selected the first potential treatment to come out of its AI-enabled research collaboration with Recursion . The molecule is an oral small-molecule treatment being developed for inflammatory disease. It was identified using Recursion’s AI-enabled drug discovery platform together with Sanofi’s expertise in immunology and drug development. The program has now entered Sanofi’s development pipeline, with a Phase 1 study planned for 2027. This is an interesting milestone because the work has progressed from computational discovery to a molecule that Sanofi believes is promising enough to take forward for further testing. For pharma R&D teams, this gives a practical way to assess AI-assisted discovery: whether the molecules identified through these platforms can move into the same development process as other potential medicines. #AIinIndustry #GenAI #EnterpriseAI #PharmaAI #DrugDiscovery #LifeSciences #Sanofi

  The next breakthrough in pharma may not come from a better molecule alone. It may come from better coordination. Drug development is an incredibly complex process. Scientific research, manufacturing, clinical trials, regulatory work, data analysis, and external partners all have to move together. And when one part changes, the consequences can ripple across the entire program. That's where the latest advances in AI are becoming particularly interesting. AI is moving beyond simply helping researchers analyze biological and chemical questions. It's increasingly being designed to connect scientific insights with the operational workflows that turn those insights into medicines. A recent example is Orchestra Bio, whose technology is designed to help biopharma teams track studies, identify downstream impacts when something changes, and surface potential next steps. And now, OpenAI has acquired Orchestra Bio, bringing its team and technology into its life-sciences platform, Rosalin...